Introduction: Mesenchymal stromal (stem) cell (MSC) therapies are emerging as a promising
therapeutic intervention in patients with Acute Respiratory Distress Syndrome (ARDS) and …

The severe respiratory consequences of the coronavirus disease 2019 (COVID-19)
pandemic have prompted the urgent need for novel therapies. Cell-based therapies …

Acute respiratory distress syndrome (ARDS) causes respiratory failure, which is associated
with severe inflammation and lung damage and has a high mortality and for which there is …

There is considerable interest in the potential for cell-based therapies, particularly
mesenchymal stromal cells (MSCs) and their products, as a therapy for acute respiratory …

Sepsis is defined as life-threatening organ dysfunction caused by a deregulated immune
host response to infection. The emergence of the severe acute respiratory syndrome …

Acute respiratory distress syndrome (ARDS) develops rapidly and has a high mortality rate.
Survivors usually have low quality of life. Current clinical management strategies are …

Despite extensive research on candidate pharmacological treatments and a significant and
increasing prevalence, sepsis syndrome, and acute respiratory distress syndrome (ARDS) …

Mesenchymal stem/stromal cells (MSCs) have become the focus of intense research effort
over the past 10 years, in an effort to harness their regenerative and immune-modulating …

Mesenchymal stromal cells (MSC) have shown potential efficacy in both animal and human
trials of acute respiratory distress syndrome (ARDS). Especially during the COVID-19 …

Severe acute respiratory syndrome coronavirus-2 and the related coronavirus disease-19
(COVID-19) is a worldwide emerging situation, which was initially reported in December …